| |
|
|
|
|
|
ALPHAGAN® P 0.1, approved by the U.S. Food and Drug Administration (FDA) in 2005, and ALPHAGAN® P 0.15, approved by the FDA in 2001, are indicated to lower IOP in patients with open-angle glaucoma and ocular hypertension. They are improved formulations of ALPHAGAN® developed to further minimize drug exposure while maintaining the drug's favorable efficacy profile.
|
Company:
Date:
April 16, 2009
|
|
|
|
|
|
|
|
|
|
AZOPT® Ophthalmic suspension (brinzolamide ophthalmic suspension 1) is used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
|
Company:
Date:
April 22, 2009
|
|
|
|
|
|
|
|
|
|
Beta Blockers
|
Company:
Date:
April 21, 2009
|
|
|
|
|
|
|
|
|
|
BETIMOL® (pronounced bay-ta-mol) is a prescription eye drop medicine used to reduce pressure inside the eye in patients with ocular hypertension or open-angle glaucoma.
It is important that BETIMOL® be used exactly as your doctor tells you. Your doctor will determine how much BETIMOL® you should use and how many times per day. Be sure to follow these instructions carefully. The usual starting dose is one drop of BETIMOL® in the affected eye(s) twice a day. If your eye pressure decreases to a level acceptable by your doctor, he or she may change your dosage schedule to one drop once daily in th
|
Company:
Date:
April 21, 2009
|
|
|
|
|
|
|
|
|
|
na
|
Company:
Date:
April 22, 2009
|
|
|
|
|
|
|
|
|
|
COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is the combination of a
topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.
Dorzolamide hydrochloride is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-
methyl-4H-thieno2,3-bthiopyran-2-sulfonamide 7,7-dioxide monohydrochloride.
|
Company:
Date:
April 21, 2009
|
|
|
|
|
|
|
|
|
|
DESCRIPTION
COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is the combination of a
topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.
Dorzolamide hydrochloride is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-
methyl-4H-thieno2,3-bthiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide
hydrochloride is optically active. The specific rotation is:
|
Company:
Date:
April 22, 2009
|
|
|
|
|
|
|
|
|
|
Lower intraocular pressure
|
Company:
Date:
April 22, 2009
|
|
|
|
|
|
|
|
|
|
Istalol® is our once-daily, topical ophthalmic solution of timolol, a beta-blocking agent for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Glaucoma is a chronic disease that gradually reduces eyesight without warning and often without symptoms. If undetected and untreated, glaucoma can lead to irreversible eye damage and eventual blindness. According to the Glaucoma Research Foundation, in the United States glaucoma is the cause of an estimated 9-12 of all blindness cases and is the second leading cause of blindness. Currently, it
|
Company:
Date:
April 21, 2009
|
|
|
|
|
|
|
|
|
|
LUMIGAN®, approved by the U.S. Food and Drug Administration (FDA) in 2001, is indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Based on its efficacy and safety profile demonstrated over five years, LUMIGAN® received a first-line indication from the FDA in 2006 and is now used as an initial treatment in an increasing number of patients. LUMIGAN® offers a once-a-day dosing regimen. Maintaining once-daily dosing can be convenient for patients.
|
Company:
Date:
April 16, 2009
|
|
|
|
|
|